- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04662944
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main goal of this study is to assess to what degree disease activity assessment is influenced and supported by the enrichment of OCT images with segmentation information (i.e. by identification, highlighting and quantification of pathological fluid compartments associated with neovascular activity).
The study comprises a prospective data collection phase and a retrospective analysis of OCT images phase. The prospective observation period per patient will be up to 12 months.
The study will include 424 patients (naïve patients and patients who have been pre-treated with licensed anti-VEGFs not more than 3 years) being treated for nAMD with brolucizumab, ranibizumab, or aflibercept according to the respective drug label. Patients will be enrolled at approximately 20 centers across 5 countries.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8G 5E4
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M8X 2X3
- Novartis Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canada, H1V 1G5
- Novartis Investigative Site
-
-
-
-
-
Bonn, Germany, 53105
- Novartis Investigative Site
-
Duesseldorf, Germany, 40212
- Novartis Investigative Site
-
Gottingen, Germany, 37075
- Novartis Investigative Site
-
Muenster, Germany, 48145
- Novartis Investigative Site
-
Ulm, Germany, 89075
- Novartis Investigative Site
-
-
Baden-Wuerttemberg
-
Ludwigsburg, Baden-Wuerttemberg, Germany, 71638
- Novartis Investigative Site
-
-
-
-
-
Waterford, Ireland, 48327
- Novartis Investigative Site
-
-
Dublin 9
-
Glasnevin, Dublin 9, Ireland, D09 YN97
- Novartis Investigative Site
-
-
-
-
MI
-
Milano, MI, Italy, 20132
- Novartis Investigative Site
-
Milano, MI, Italy, 20157
- Novartis Investigative Site
-
-
-
-
-
Leon, Spain, 24080
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08035
- Novartis Investigative Site
-
Barcelona, Catalunya, Spain, 08036
- Novartis Investigative Site
-
-
Sevilla
-
Bormujos, Sevilla, Spain, 41930
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of nAMD
- Male and Female patients with ≥18 years of age at index
- Receipt of at least one injection of brolucizumab, ranibizumab or aflibercept during the recruitment period
- Signed written informed consent
- Patients for whom a therapy with brolucizumab, ranibizumab or aflibercept is medically indicated according to the respective label
- Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at screening
Exclusion Criteria:
- Patients treated for any other retinal disease than nAMD within 6 months prior to the index date (e.g. patients treated for retinal vein occlusion, diabetic macular oedema, myopic CNV, and have diagnoses of diabetes-related macular degeneration)
- Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion in the study eye at screening
- Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
- Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
- Patients who have any contraindication and are not eligible for treatment with the chosen anti-VEGF treatment as according to the respective label.
- Any medical or psychological condition, in the treating physician's opinion, which may hinder the patient from participating in this study for the expected 12 months
- Patients participating, in parallel, in an interventional clinical trial
- Patients participating, in parallel, in any other Novartis sponsored NIS generating primary data for an anti-VEGF drug
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Licensed anti-VEGFs
Patients being treated for nAMD with licensed anti-VEGFs
|
There is no treatment allocation.
Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
There is no treatment allocation.
Patients administered Ranibizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
There is no treatment allocation.
Patients administered Aflibercept by prescription that have started before inclusion of the patient into the study will be enrolled.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Odds ratio of disease activity identification from Optical Coherence Tomography (OCTs) with and without automatic augmentation
Time Frame: 12 months
|
An odds ratio of disease activity identification from OCTs with and without automatic segmentation will be reported with a 95% confidence interval.
|
12 months
|
Degree of agreement in classification of disease activity using segmented OCT images
Time Frame: 12 months
|
Degree of agreement in classification of disease activity assessed by Krippendorff's alpha using segmented OCT images
|
12 months
|
Degree of agreement in classification of disease activity using non-segmented OCT images
Time Frame: 12 months
|
Degree of agreement in classification of disease activity assessed by Krippendorff's alpha using non-segmented OCT images
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess if Discovery is accepted by physicians and whether it can optimize the ophthalmic clinical workflow
Time Frame: Month 12
|
Physicians will use a digital solution Discovery for managing imaging data and automatic segmentation of OCT volumes.
To understand if such a tool is well suited for its role in its current form, holds value for physicians and can optimize clinical workflow, physicians will be invited to complete questionnaires regarding their user experience.
|
Month 12
|
Percentage (%) of patients absent of Subretinal Fluid, Intraretinal Fluid and Pigment Epithelium Detachment
Time Frame: Month 12
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
Month 12
|
Estimate Central Subfield Thickness (CST) change and correlation with Visual Acuity (VA)
Time Frame: 12 months
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
12 months
|
Visual Acuity (VA) change from baseline
Time Frame: Baseline, month 12
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
Baseline, month 12
|
Percentage (%) of patients with ocular and non-ocular adverse events
Time Frame: 12 months
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRTH258A2402
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheNot yet recruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, Italy, Argentina, Spain, United Kingdom, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Iconic Therapeutics, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
Clinical Trials on brolucizumab
-
Novartis PharmaceuticalsNot yet recruiting
-
Novartis PharmaceuticalsTerminatedNeovascular Age-related Macular DegenerationUnited Kingdom
-
Novartis PharmaceuticalsActive, not recruitingDiabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD)Germany
-
Novartis PharmaceuticalsActive, not recruitingNeovascular Age-related Macular Degeneration (nAMD)Portugal
-
Novartis PharmaceuticalsRecruitingNeovascular Age-related Macular DegenerationUnited Arab Emirates
-
Novartis PharmaceuticalsWithdrawn
-
Novartis PharmaceuticalsCompletedAge-related Macular DegenerationGermany, Switzerland
-
Novartis PharmaceuticalsActive, not recruitingDiabetic Macular EdemaJapan
-
Novartis PharmaceuticalsRecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States